Investigational developments for the treatment of progesteron-dependent diseases

Expert Opinion on Investigational Drugs

Volumn 17, Issue 4, 2008, Pages 469-479

  Möller, Carsten ^a   Hoffmann, Jens ^a   Kirkland, Thomas A ^a   Schwede, Wolfgang ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Breast cancer; Endometriosis; Progesterone receptor; Progesterone receptor antagonists; Selective progesterone receptor modulator; Uterine fibroids

Indexed keywords

11BETA (4 ACETYLPHENYL) 17BETA HYDROXY 17ALPHA (1,1,2,2,2 PENTAFLUOROETHYL)ESTRA 4,9 DIEN 3 ONE; 17ALPHA ACETOXY 11BETA (4 DIMETHYLAMINOPHENYL) 21 METHOXY 19 NORPREGNA 4,9 DIENE 3,20 DIONE; ANTIGESTAGEN; ASOPRISNIL; CBD 2914; DANAZOL; ESTROGEN; GONADORELIN AGONIST; HORMONE RECEPTOR BLOCKING AGENT; MIFEPRISTONE; NONSTEROID ANTIINFLAMMATORY AGENT; ONAPRISTONE; PLACEBO; PRA 910; PROGESTERONE; PROGESTERONE RECEPTOR MODULATOR; RWJ 26329; TAMOXIFEN; TANAPROGET; ULIPRISTAL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HORMONE ANTAGONIST; LIGAND; NEW DRUG; PROGESTERONE RECEPTOR;

ANTIGLUCOCORTICOID SIDE EFFECT; BONE DISEASE; BONE MASS LOSS; BREAST CANCER; CANCER HORMONE THERAPY; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; ENDOCRINE DISEASE; ENDOMETRIOSIS; ESTROGEN DEFICIENCY; FEMALE; HOT FLUSH; HUMAN; HYPOESTROGENICITY; LIVER FUNCTION TEST; LOW DRUG DOSE; NONHUMAN; OVARIECTOMY; PELVIS PAIN SYNDROME; PUBLICATION; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION; UTERUS MYOMA; ANIMAL; BREAST TUMOR; CELL PROLIFERATION; CHEMICAL STRUCTURE; DRUG ANTAGONISM; DRUG EFFECT; LEIOMYOMA; METABOLISM; PARTIAL AGONISM; UTERUS CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG PARTIAL AGONISM; DRUGS, INVESTIGATIONAL; ENDOMETRIOSIS; FEMALE; HORMONE ANTAGONISTS; HUMANS; LEIOMYOMA; LIGANDS; MOLECULAR STRUCTURE; PROGESTERONE; RECEPTORS, PROGESTERONE; STRUCTURE-ACTIVITY RELATIONSHIP; UTERINE NEOPLASMS;

EID: 42149122613     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.4.469     Document Type: Review

References (75)

1. Pike AC, Brzozowski AM, Hubbard RE, et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 1999;18:4608-18
2. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1999;95:927-37
3. Brzozowski AM, Pike AC, Daute Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753-8
4. Madauss KP, Grygielko ET, Deng SJ, et al. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol Endocrinol 2007;21:1066-81
5. Horwitz KB, Alexander PS. In situ photolinked nuclear progesterone receptors of human breast cancer cells: subunit molecular weights after transformation and translocation. Endocrinology 1983;113:2195-201
6. Kastner P, Krust A, Turcotte B, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990;9:1603-14
7. Cenneely OM, Maxwell BL, Toft DO, et al. The A and B forms of the chicken progesterone receptor arise by alternate initiation of translation of a unique MRNA. Biochem Biophys Res Commun 1987;149:493-501
8. Sartorius CA, Melville MY, Hovland AR, et al. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol Endocrinol 1994;8:1347-60
9. Bain DL, Franden MA, McManaman JL, et al. The N-terminal region of human progesterone B-receptors: biophysical and biochemical comparison to A-receptors. J Biol Chem 2001;276:23825-31
10. Tung L, Shen T, Abel MG, et al. Mapping the unique activation function 3 in the progesterone B-receptor upstream segment. Two LXXLL motifs and a tryptophan residue are required for activity. J Biol Chem 2001;276:39843-51
11. Takimoto GS, Tung L, Abdel-Hafiz H, et al. Functional properties of the N-rerminal region of progesterone receptors and their mechanistic relationship to structure. J Steroid Biochem Mol Biol 2003;85:209-19
12. Conneely OM, Mulac-Jericevic B, Demayo F, et al. Reproductive functions of progesterone receptors. Recent Prog Horm Res 2002;57:339-55
13. Fernandez-Valdivia R, Mukherjee A, Mulac-Jericevic B, et al. Revealing progesterones role in uterine and mammary gland biology: insights from the mouse. Semin Reprod-Med 2005;23:22-37
14. Chappell PE, Lydon JP, Conneely OM, et al. Endocrine defects in mice carrying a null mutation for the progesterone receptor gene. Endocrinology 1997;138:4147-52
15. Lydon JP, Demayo FJ, Funk CR, et al. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 1995;9:2266-78
16. Mulac-Jericevic B, Mullinax RA, Demayo FJ, et al. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 2000;289:1751-4
17. Mulac-Jericevic B, Lydon JP, Demayo FJ, Conneely OM. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci USA 2003;100:9744-9
18. Conneely OM, Mulac-Jericevic B, Lydon JP. Progesterone-dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms. Steroids 2003;68:771-8
19. Chwalisz K, Brenner RM, Fuhrmann U, et al. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 2000;65:741-51
20. Elger W, Bartley J, Schneider B, et al. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids 2000;65:713-23
21. Herrmann W, Wyss R, Riondel A, et al. The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy. C R Seances Acad Sci III 1982;294:933-8
22. Belanger A, Philibert D, Teutsch G. Regio and stereospecific synthesis of 11 beta-substituted 19-norsteroids. Influence of 11 beta-substitution on progesterone receptor affinity - (1). Steroids 1981;37:361-82
23. Wiechert R, Neef G. Synthesis of antiprogestational steroids. J Steroid Biochem 1987;27:851-8
24. Kloosterboer HJ, Deckers GH, De Gooyer ME, et al. Pharmacological properties of a new selective antiprogestagen: Org 33628. Ann NY Acad Sci 1995;761:192-201
25. Fuhrmann U, Hess-Stump H, Cleve A, et al. Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem 2000;43:5010-6
26. Maibauer R, Zurth C, Schultze-Mosgau M, et al. First human data for ZK 230211 (ZK-PRA), a new progesterone receptor antagonist: a Phase I clinical analysis of safety and pharmacokinetics in healthy post-menopausal women. San Antonio Breast Cancer Symposium, USA; 2006 Dec 14-17
27. Repros Therapeutics, Inc. Available from: http://www.reprosrx.com/ [Last accessed 26 February 2008]
28. Winneker RC, Fensome A, Wrobel JE, et al. Nonsteroidal progesterone receptor modulators: structure activity relationships. Semin Reprod Med 2005;23:46-57
29. Allan GF, Sui Z. Non-steroidal progesterone receptor specific ligands. Mini Rev Med Chem 2005;5:701-8
30. Zhang P, Terefenko EA, Fensome A, et al. 6-Aryl-1,4-dihydro-benzo[d][1,3] oxazin-2-ones: a novel class of potent, selective, and orally active nonsteroidal progesterone receptor antagonists. J Med Chem 2002;45:4379-82
31. Zhang Z, Olland AM, Zhu Y, et al. Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget. J Biol Chem 2005;280:28468-75
32. Palmer S, Campen CA, Allan GF, et al. Nonsteroidal progesterone receptor ligands with unprecedented receptor selectivity. J Steroid Biochem Mol Biol 2000;75:33-42
33. Jones DG, Liang X, Stewart EL, et al. Discovery of non-steroidal mifepristone mimetics: pyrazoline-based PR antagonists. Bioorg Med Chem Lett 2005;15:3203-6
34. Orihuela PA. Ulipristal, a progesterone receptor antagonist as a contraceptive and for the treatment of uterine fibroids. Curr Opin Investig Drugs 2007;8:859-66
35. Lydon JP, Ge G, Kittrell FS, et al. Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res 1999;59:4276-84
36. Schneider EG, Armant DR, Kupper TS, Polan ML. Absence of a direct effect of recombinant interleukins and cultured peritoneal macrophages on early embryonic development in the mouse. Biol Reprod 1989;40:825-33
37. Hofmann J, Lichtner RB, Fuhrmann U, et al. Effects of progesterone receptor antagonists on breast cancer. In: Endocrine Management of Breast Cancer. Robertson JFR, Nicholson RI, Hayes DF, editors. London: Martin Dunitz; 2002. p. 247-62
38. Hoffmann J, Sommer A. Steroid hormone receptors as targets for the therapy of breast and prostate cancer - recent advances, mechanisms of resistance, and new approaches. J Steroid Biochem Mol Biol 2005;93;191-200
39. Michna H, Nishino Y, Neef G, et al. Progesterone antagonists: tumor-inhibiting potential and mechanism of action. J Steroid Biochem Mol Biol 1992;41:339-48
40. Michna H, Parczyk K, Schneider MR, Nishino Y. Differentiation therapy with progesterone antagonists. Ann NY Acad Sci 1995;761:224-47
41. El Etreby MF, Liang Y. Effect of antiprogestins and tamoxifen on growth inhibition of MCF-7 human breast cancer cells in nude mice. Breast Cancer Res Treat 1998;49:109-17
42. Bergers E, Baak JP, Van Diest PJ, et al. Prognostic implications of different cell cycle analysis models of flow cytometric DNA histograms of 1,301 breast cancer patients: results from the Multicenter Morphometric Mammary Carcinoma Project (MMMCP). Int J Cancer 1997;74:260-9
43. Klijn JG, Setyono-Han B, Sander HJ, et al. Pre-clinical and clinical treatment of breast cancer with antiprogestins. Hum Reprod 1994;9(Suppl 1):181-9
44. Robertson JF, Willsher PC, Winterbottom L, et al. Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer 1999;35:214-8
45. Jonar W, Giurescu M, Robertson JFR. The clinical efficacy of progesterone antagonists in breast cancer. In: Endocrine Management of Breast Cancer. Robertson JFR, Nicholson RI, Hayes DF, editors. London: Martin Dunitz; 2002. p. 117-224
46. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990;94:435-8
47. Wilcox LS, Koonin LM, Pokras R, et al. Hysterectomy in the United States, 1988-1990. Obstet Gynecol 1994;83:549-55
48. Olive DL, Lindheim SR, Pritts EA. Non-surgical management of leiomyoma: impact on fertility. Curr Opin Obstet Gynecol 2004;16:239-43
49. Brandon DD, Bethea CL, Strawn EY, et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 1993;169:78-85
50. Englund K, Blanck A, Gustavsson I, et al. Sex steroid receptors in human myomecrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab 1998;83:4092-6
51. Ichimura T, Kawamura N, Ito F, et al. Correlation between the growth of uterine leiomyomata and estrogen and progesterone receptor content in needle biopsy specimens. Fertil Steril 1998;70:967-71
52. Friedman AJ, Barbieri RL, Doubilet PM, et al. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 1988;49:404-9
53. Carr BR, Marshburn PB, Weatherall PT, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993;76:1217-23
54. Kawaguchi K, Fujii S, Konishi I, et al. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989;160:637-41
55. Maruo T, Matsuo H, Samoto T, et al. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids 2000;65:585-92
56. Kurachi O, Matsuo H, Samoto T, Maruo T. Tumor necrosis factor-alpha expression in human uterine leiomyoma and its down-regulation by progesterone. J Clin Endocrinol Metab 2001;86:2275-80
57. Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 2004;103:1331-6
58. Fiscella K, Eisinger SH, Meldrum S, et al. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 2006;108:1381-7
59. Chwalisz K, Larsen L, Mattia-Goldberg C, et al. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 2007;87:1399-412
60. Garai J, Molnar V, Varga T, et al. Endometriosis: harmful survival of an ectopic tissue. Front Biosci 2006;11:595-619
61. Jones G, Kennedy S, Barnard A, et al. Development of an endometriosis quality-of-life instrument: The Endometriosis Health Profile-30. Obstet Gynecol 2001;98:258-64
62. Kettel LM, Murphy AA, Mortola JF, et al. Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis. Fertil Steril 1991;56:402-7
63. Kettel LM, Murphy AA, Morales AJ, et al. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 1996;65:23-8
64. Kettel LM, Murphy AA, Morales AJ, Yen SS. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol 1998;178:1151-6
65. Chwalisz K, Mattia-Goldberg K, Lee M, et al. Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisnil [abstract 0-207]. Fertil Steril 2004;82:S83
66. Hodgen GD, Van Uem JF, Chillik CF, et al. Non-competitive anti-oestrogenic activity of progesterone antagonists in primate models. Hum Reprod 1994;9(Suppl 1):77-81
67. Slayden OD, Zelinski-Wooten MB, Chwalisz Y, et al. Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: morphometric assessment of the uterus and oviduct. Hum Reprod 1998;13:269-77
68. Slayden OD, Brenner RM. RU 486 action after estrogen priming in the endometrium and oviducts of rhesus monkeys (Macaca mulatta). J Clin Endocrinol Metab 1994;78:440-8
69. Narvekar N, Cameron S, Critchley HO, et al. Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor. J Clin Endocrinol Metab 2004;89:2491-7
70. Baird DT, Brown A, Critchley HO, et al. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 2003; 18:61-8
71. Horne FM, Blithe DL. Progesterone receptor modulators and the endometrium: changes and consequences. Hum Reprod Update 2007;13:567-80
72. Lakha F, Ho PC, Van Der Spuy ZM, et al. A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Reprod 2007;22:2428-36
73. Eisinger SH; Meldrum S, Fiscella K, et al. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 2003;101:243-50
74. Eisinger SH, Bonfiglio T, Fiscella K, et al. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005;12:227-33
75. Williams AR, Critchley HO, Osei J, et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod 2007;22:1696-704